Compare Amylx Pharmaceuticals Inc (AMLX) vs Alphabet Inc Class A (GOOGL) Price & Performance

AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.

Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.

Alphabet (GOOGL) is trading at $341.48, down 4.49% over the past 24 hours, with a bearish technical signal. The company demonstrates strong fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Recent earnings beats and a 85% analyst buy rating support the positive outlook, though technical indicators show near-term pressure with support at $341 and resistance at $350.

GOOGL presents a compelling long-term investment opportunity with robust profitability (54.77% net margin) and AI-driven growth potential, though investors face near-term technical weakness and regulatory risks. The consensus price target of $426.28 implies significant upside from current levels, supported by strong cash flow generation and strategic AI investments.